RenalytixRNLX
Market Cap: $24.8M
About: Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the common and costly chronic medical conditions globally. The company's product is KidneyIntelX which is being designed to make improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.
Employees: 110
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
1.81% less ownership
Funds ownership: 4.05% [Q1] → 2.24% (-1.81%) [Q2]
4% less funds holding
Funds holding: 26 [Q1] → 25 (-1) [Q2]
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
77% less capital invested
Capital invested by funds: $3.47M [Q1] → $799K (-$2.67M) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Yi Chen 32% 1-year accuracy 44 / 139 met price target | 902%upside $3 | Buy Reiterated | 12 Jul 2024 |